Welcome to our dedicated page for IMMUCELL /DE/ SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IMMUCELL /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IMMUCELL /DE/'s regulatory disclosures and financial reporting.
ImmuCell Corp director David Scott Tomsche received a grant of 10,000 stock options as compensation. These non-qualified stock options give him the right to buy 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share. Following this award, his reported derivative holdings from this grant total 10,000 options, which become exercisable on April 16, 2028 and expire on April 16, 2030. This is a routine equity incentive award rather than an open-market share purchase or sale.
ImmuCell Corp. vice president Bobbi Jo Brockmann received a grant of 5,000 incentive stock options for company common stock. The options carry an exercise price of $5.49 per share and relate to 5,000 underlying common shares. They are reported as directly owned and expire on April 16, 2030.
ImmuCell Corp. director Steven T. Rosgen received a grant of 10,000 non-qualified stock options on Common Stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this compensation-related award, he holds 10,000 options directly.
ImmuCell Corp. director Gloria F. Basse received a grant of 10,000 non-qualified stock options on Common Stock. These options were awarded as compensation at an exercise price of $5.49 per share, allowing her to buy up to 10,000 shares at that price if she chooses to exercise.
After this award, she holds options on 10,000 shares in total, with the options scheduled to become exercisable on April 16, 2028 and expiring on April 16, 2030. This is a routine equity incentive grant rather than an open-market stock purchase or sale.
ImmuCell Corporation announced significant Board changes and governance updates. Three long-serving directors, including former President and CEO Michael Brigham and Vice President of Sales and Marketing Bobbi Jo Brockmann, will retire from the Board effective April 15, 2026, while remaining executives where applicable.
The Company appointed two new directors, Dr. Gilles Guillemette and Dr. Anthony DiMarco, both with extensive animal health and biologics experience. ImmuCell is moving to a 7-person Board with six Independent Directors and the CEO, and is creating a new Strategy and Technology Committee to support innovation and manufacturing improvements.
ImmuCell Corporation reported strong preliminary sales growth for the first quarter of 2026. Total product sales for the three months ended March 31, 2026 were $10.4 million, up from $8.1 million a year earlier, a 28.4% increase. Growth was driven mainly by Tri-Shield® First Defense®, which generated $7.9 million in sales, a 38.5% increase compared to the prior-year period.
Domestic sales were $9.7 million, up 35.7%, while international sales declined to $0.6 million, down 30.2%. Management cited strong seasonal demand from the cow-calf segment and improved inventory and manufacturing strategies, while noting that previous backlogs still complicate growth comparisons.
IMMUCELL CORP /DE/ filed an initial Form 3 reporting that Kathy V. Turner is a director of the company. The filing does not list any equity holdings or report any transactions in the company’s securities, serving mainly as a baseline disclosure of insider status.
ImmuCell Corporation reported 2025 product sales of $27.6 million, up 4.3% from 2024, driven mainly by higher Tri‑Shield® demand after clearing prior production backlogs. Gross margin improved from 30% to 41% of product sales as manufacturing efficiency and capacity increased to 4.6 million manufactured units.
The company pivoted strategically in December 2025 to focus on its First Defense® calf‑health franchise and paused further investment in manufacturing Re‑Tain®, recording a $2.7 million non‑cash impairment on related assets. Despite this charge, net loss narrowed to $1.0 million from $2.2 million in 2024, and net operating income turned positive at $1.6 million.
ImmuCell ended 2025 with $3.8 million in cash, net working capital of $13.0 million, and bank debt of $9.1 million at a blended fixed rate of 4.31%. The firm relies heavily on First Defense®, which represented 99% of product sales, and serves a growing biological scours‑prevention market where it estimates about 55% of U.S. calves are still not protected.
ImmuCell director Michael F. Brigham reported a routine stock option exercise. He exercised options for 25,000 shares of Common Stock at $5.84 per share, using previously owned shares to pay the exercise price. In connection with this, 24,052 shares were surrendered to the company to satisfy the option exercise price or related obligations. After these transactions, he directly holds 205,700 shares of ImmuCell Common Stock.
ImmuCell Corp filed an amended insider report showing that President and CEO Paul Francis Olivier te Boekhorst received a grant of 109,500 stock options on January 27, 2026 at an exercise price of $6.265 per share. This amendment corrects the previously reported number of options.
The options were granted in connection with his role as President and CEO. All of the options vest only if ImmuCell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year, making this a fully performance-based award.